Skip to main content

Esmolol Hydrochloride (Monograph)

Brand name: Brevibloc
Drug class: beta-Adrenergic Blocking Agents

Medically reviewed by Drugs.com on Jun 10, 2024. Written by ASHP.

Introduction

Short-acting β1-selective adrenergic blocking agent.1 2 17 18 113

Uses for Esmolol Hydrochloride

Supraventricular Arrhythmias

Rapid, temporary control of ventricular rate in patients with supraventricular tachycardia (SVT) (e.g., atrial flutter and/or fibrillation, sinus tachycardia, junctional tachycardia, atrial tachycardia).1 2 53 54 55 56 57 58 59 68 87 88 100 113 300 301

Vagal maneuvers and/or IV adenosine are considered first-line interventions for acute treatment of SVT when clinically indicated; if such measures are ineffective or not feasible, may consider an IV β-adrenergic blocking agent.300 Although evidence of efficacy is limited, experts state that overall safety of β-blockers warrants use.300

May be used in patients with nonpreexcited atrial flutter and/or fibrillation to control rapid heart rate associated with surgical or other manipulative procedures (e.g., cardiac catheterization), or other emergent situations requiring short-term control of ventricular rate.1 2 5 51 52 53 54 55 56 57 58 59 68 87 88 100 113 300 301

May be useful in patients with noncompensatory sinus tachycardia for short-term control of rapid heart rate requiring intervention.1 2 37 59 60 61 62 63 64 65 66 67 68

Not intended for chronic use when other more appropriate antiarrhythmic agents would be preferred.1 2

Hypertension

Treatment of intraoperative and postoperative hypertension and/or tachycardia.74 109 113 542 a Has been used effectively for prevention or treatment of increases in BP associated with surgical events.63 64 71 72 73 74 75 109 113 125 However, use for prevention of such events is not recommended by the manufacturer.a

Management of hypertensive emergencies in adults.542 1200

Rapid reduction of BP in the management of acute severe hypertension in pediatric patients† [off-label] with life-threatening symptoms.1150

Treatment to produce controlled hypotension† [off-label] during anesthesia in order to reduce bleeding resulting from surgical procedures (e.g., orthopedic surgery, neurosurgery).75 114 124

Acute Myocardial Ischemia

Has been used for the management of acute tachyarrhythmias complicating acute MI† [off-label]15 24 25 and to minimize myocardial ischemia following acute MI† [off-label]13 15 24 25 58 113 or associated with unstable angina† [off-label].15 24 58 82 113

While current expert guidelines recommend an oral β-blocker in all patients with MI who do not have manifestations of heart failure, evidence of low-output state, increased risk of cardiogenic shock, or any other contraindications to β-blocker therapy, use of IV β-blockers should be limited to patients with refractory hypertension or ongoing ischemia. 527 1100

Esmolol Hydrochloride Dosage and Administration

General

Hypertensive Emergency and Acute Severe Hypertension

Administration

Administer by IV infusion.1

May administer by direct IV injection for immediate control of intraoperative tachyarrhythmia and/or hypertension.a

Continuous infusion is preferred for rapid BP reduction in children† due to short duration of action.1150

IV Administration

IV infusion usually administered via controlled infusion device to facilitate dosage titration.52 53 54 61 114 126

Take care to avoid extravasation.600 Avoid using butterfly needles and very small veins for infusion.1 114 Use alternate infusion site if local reaction occurs at infusion site.1 Severe infusion site reactions have occurred, particularly after extravasation (see Extravasation under Cautions).600

Do not introduce additives into premixed solutions in ready-to-use bags.1 a

Do not use the premixed injection in series connections with other plastic containers since such use could result in air embolism.1

Infusion bag for premixed solution contains 2 outlet ports.1 Use medication port on the bag only for withdrawing an initial loading dose for direct IV injection.a Sterility cannot be guaranteed with repeated withdrawals; once drug has been withdrawn from the bag, use the solution within 24 hours.a

Esmolol hydrochloride injection (10 mg/mL) in ready-to-use vials may be used to administer loading doses.600

Rate of Administration

Administer 500-mcg/kg loading doses over 1 minute, followed by IV infusion of the drug.a Rate of IV infusion determined by patient response and tolerance.1 51 52 53 54 55 58 59 60 61 64 65 66 67 68

For immediate control of intraoperative or postoperative hypertension and/or tachycardia, administer initial 1-mg/kg loading dose by IV injection over 30 seconds, followed by IV infusion, if necessary.600

Standardize 4 Safety

Standardized concentrations for esmolol have been established through Standardize 4 Safety (S4S), a national patient safety initiative to reduce medication errors, especially during transitions of care.249 250 Because recommendations from the S4S panels may differ from the manufacturer’s prescribing information, caution is advised when using concentrations that differ from labeling, particularly when using rate information from the label.249 250 For additional information on S4S (including updates that may be available), see [Web].249 250

dosing units differ from concentration units

Table 1: Standardize 4 Safety Continuous IV Infusion Standard Concentrations for Esmolol249250

Patient Population

Concentration Standards

Dosing Units

Adults

10 mg/mL

mcg/kg/min

20 mg/mL

Pediatric patients (<50 kg)

10 mg/mL

mcg/kg/min

20 mg/mL

Dosage

Available as esmolol hydrochloride; dosage expressed in terms of the salt.a

Pediatric Patients

Acute Severe Hypertension
Rapid Reduction of BP†
IV

Children and adolescents: 100–500 mcg/kg per minute as continuous infusion.1150

Adults

SVT
IV

Loading dose of 500 mcg/kg per minute for 1 minute,1 51 52 53 54 55 58 300 301 followed by maintenance infusion of 50 mcg/kg per minute for 4 minutes.1 2 3 51 52 53 54

If desired response is not attained within first 5 minutes, may increase infusion rate in 50-mcg/kg per minute increments (i.e., to 100 mcg/kg per minute, then to 150 mcg/kg per minute) up to a maximum of 200 mcg/kg per minute; maintain each new rate for 4 or more minutes.1

Adjust rate and duration of infusion carefully according to patient’s tolerance and response (as indicated by ventricular rate and BP).1 51 52 53 54 55 58

Average maintenance dosage: 100 mcg/kg per minute (range: 50–200 mcg/kg per minute).1 2 3 51 52 53 54 55 58 Maintenance dosages up to 300 mcg/kg per minute have been used occasionally.1 2 3 51 52 53 54 55 58 300 301 Adequate rate control may occur with dosage as low as 25 mcg/kg per minute.1 55

Transfer to alternative antiarrhythmic therapy (e.g., longer-acting β-blocker, digoxin, verapamil) when adequate control of heart rate has been achieved and patient is stabilized.1

Rapid Dosage Titration (if rapid slowing of ventricular response is required)
IV

Loading dose of 500 mcg/kg per minute for 1 minute,1 51 52 53 54 55 58 followed by maintenance infusion of 50 mcg/kg per minute for 4 minutes.1 2 3 51 52 53 54

Administer second loading dose of 500 mcg/kg per minute for 1 minute,1 2 3 51 52 53 54 followed by maintenance infusion of 100 mcg/kg per minute for 4 minutes.1 2 3 51 52 53 54

If necessary, administer a third and final loading dose of 500 mcg/kg per minute for 1 minute, followed by 150 mcg/kg per minute for 4 minutes.1 52 55 57 58

If needed (without a fourth loading dose), increase maintenance dosage to maximum of 200 mcg/kg per minute.1 52 55 57 58

Once the desired ventricular rate1 or a patient tolerance end point (e.g., reduction in BP)52 53 54 has been nearly achieved,1 114 omit loading doses and titrate maintenance infusion rate upward (to 200 mcg/kg per minute) or downward as appropriate; may increase interval between dosage increments.1

Transfer to Alternative Antiarrhythmics
IV

Decrease esmolol infusion rate by 50% 30 minutes after the first dose of the alternative drug; if adequate response is maintained for ≥1 hour after the second dose of the alternative drug, discontinue esmolol.1

Consider dosing guidelines for the alternative drug when determining the appropriateness of this guideline for transferring therapy.1

Hypertension
Immediate Control of Intraoperative and Postoperative Hypertension and/or Tachycardia
IV

1 mg/kg by direct IV injection over 30 seconds; if necessary, follow with IV infusion of 150 mcg/kg per minute.600

Adjust as required to maintain desired heart rate (maximum 200 mcg/kg per minute) and/or BP (maximum 300 mcg/kg per minute).600

Gradual Control of Intraoperative and Postoperative Hypertension and/or Tachycardia
IV

Loading dose of 500 mcg/kg per minute for 1 minute followed by maintenance infusion of 50 mcg/kg per minute for 4 minutes.a If desired response is not attained within first 5 minutes, administer second loading dose of 500 mcg/kg per minute for 1 minute followed by maintenance infusion of 100 mcg/kg per minute.a

Adjust dosage using titration schedule recommended for treatment of SVT;1 however, higher dosages (e.g., 250–300 mcg/kg per minute) may be required for adequate control of BP.1

Hypertensive Emergency
IV

Loading dose of 500–1000 mcg/kg over 1 minute, followed by 50 mcg/kg per minute by IV infusion; may repeat loading dose and increase infusion rate in increments of 50 mcg/kg per minute as needed to a maximum of 200 mcg/kg per minute.1200

Production of Controlled Hypotension† during Anesthesia
IV

Dosage has been titrated upward to a level necessary to maintain the required reduction in BP (e.g., a 15% reduction in mean arterial pressure) or until maximum rate of 300 mcg/kg per minute is reached.75 124 126

Prescribing Limits

Adults

SVT
IV

Manufacturer recommends maximum maintenance dosage of 200 mcg/kg per minute.a Maintenance dosages as high as 300 mcg/kg per minute have been used1 2 3 51 52 53 54 55 58 but provide little added benefit and increase the incidence of adverse effects.1 2 51 53 58 114 Safety of maintenance dosages >300 mcg/kg per minute not established.1 3

Administered for ≤24 hours in most patients;1 2 55 limited data indicate that infusions may be well tolerated for up to 48 hours.1

Hypertension
Intraoperative and Postoperative Hypertension and/or Tachycardia
IV

Tachycardia: Maximum 200 mcg/kg per minute.600 Higher dosages provide little additional benefit in lowering heart rate but increase risk of adverse effects.600

Hypertension: Safety of dosages >300 mcg/kg per minute not established.600

Hypertensive Emergency
IV

Maximum 200 mcg/kg per minute.1200

Special Populations

Renal Impairment

Administer with caution, especially in patients with severe renal impairment.1 2

Detailed Esmolol dosage information

Cautions for Esmolol Hydrochloride

Contraindications

Warnings/Precautions

Warnings

Hypotension

Risk of hypotension,1 2 24 50 51 54 55 56 57 58 59 63 100 113 114 122 occasionally symptomatic (e.g., manifested as diaphoresis or dizziness).1 2 50 51 54 55 58 Can occur at any dose level but usually is dose related.1 2 51 53 58 Doses >200 mcg/kg per minute not recommended by manufacturer for SVT management.1 2 114

Dosage reduction or discontinuance of drug usually results in reversal of hypotension within 30 minutes.1

Monitor BP closely, especially in patients with low pretreatment BP (e.g., SBP <105 mm Hg).1 2 55 58 114

Intraoperative or Postoperative Hypertension

Do not use when hypertension is principally due to hypothermia-associated vasoconstriction.1

Cardiac Failure

Possible precipitation of heart failure in patients with inadequate cardiac function; use with caution in such patients.1 2 Prolonged β-adrenergic blockade may lead to cardiac failure in patients with latent cardiac insufficiency.104

Avoid use in patients with overt heart failure.1 Use cautiously, if necessary, in patients with compensated heart failure (e.g., those controlled with cardiac glycosides and/or diuretics).1

Discontinue at first sign or symptom of impending cardiac failure;1 if necessary, initiate specific therapy (e.g., a cardiac glycoside and/or diuretic).1 2 If continued esmolol therapy is necessary, may restart esmolol infusion at a slower rate once manifestations of cardiac failure have subsided.114

Bronchospastic Disease

In general, do not use β-blockers in patients with bronchospastic disease;1 2 105 106 107 116 117 however, may use esmolol with caution due to its relative β1-selective adrenergic blocking activity and short duration of action.1 2 Administer lowest effective dose since β1-selectivity is not absolute.1 2

Discontinue immediately if bronchospasm occurs.1 May administer a β2-adrenergic agonist (bronchodilator), but use extreme caution since the patient may have a preexisting rapid ventricular rate.1 2

Diabetes and Hypoglycemia

Possible decreased signs and symptoms of hypoglycemia (e.g., tachycardia, palpitation, BP changes, tremor, feelings of anxiety, but not sweating or dizziness) and increased insulin-induced hypoglycemia.1 2 108

Use with caution in patients with diabetes mellitus or hypoglycemia.1 2

General Precautions

Adverse effects generally resolve more rapidly than with other β-blockers because of esmolol’s short duration of action.1 2 3 4 5 113

Cardiovascular Precautions

Use with caution in patients with SVT who are compromised hemodynamically or are taking drugs that reduce peripheral resistance, myocardial filling, myocardial contractility, and/or electrical impulse propagation in the myocardium.1

Use IV β-blockers, including esmolol, with caution in patients with acute atrial fibrillation who have overt congestion, hypotension, or heart failure with reduced ejection fraction.301

Deaths have been reported in patients with complex clinical states receiving esmolol (presumably to control ventricular rate).1

History of Anaphylactic Reactions

Patients with a history of severe anaphylactic reactions to a variety of allergens may be more reactive to repeated, accidental, diagnostic, or therapeutic challenge with such allergens and less responsive to usual doses of epinephrine.1

Abrupt Withdrawal of Therapy

Abrupt discontinuance has not produced the withdrawal effects (e.g., exacerbation of angina symptoms, precipitation of MI) associated with abrupt discontinuance of other β-adrenergic blocking agents used chronically.1 However, consider the possibility that such effects could occur with esmolol in patients with coronary artery disease; use caution when esmolol infusions are stopped abruptly in such patients.1

Extravasation

Avoid extravasation.1 Infusion site reactions, including irritation, inflammation, and severe reactions (e.g., thrombophlebitis, necrosis, blistering), have occurred, particularly following extravasation.600 (See IV Administration under Dosage and Administration.)

Specific Populations

Pregnancy

Category C.a

Lactation

Not known whether esmolol is distributed into milk.1 Use with caution in nursing women.1

Pediatric Use

Safety and efficacy not established in children <18 years of age.1 114

May cause profound bradycardia when used for rapid reduction of BP in pediatric patients with acute severe hypertension† .1150

Renal Impairment

Use with caution in patients with renal impairment, especially severe impairment; de-esterified metabolite (ASL 8123) is eliminated mainly by the kidneys.1 2 47

Common Adverse Effects

Hypotension,1 2 24 50 51 53 54 55 56 57 58 59 63 100 113 114 122 dizziness,1 2 51 54 55 58 113 122 diaphoresis,1 2 50 51 54 55 58 113 122 headache,1 2 51 55 58 59 113 somnolence,1 2 50 55 58 113 confusion,1 2 55 58 113 agitation,1 2 55 58 63 113 nausea,1 2 51 55 56 58 59 113 infusion site reactions1 2 (e.g., inflammation,1 2 54 55 58 induration).1 2 55 58 59

Drug Interactions

Specific Drugs

Drug

Interaction

Comments

Digoxin

Possible increase in serum digoxin concentrations;1 2 49 113 esmolol pharmacokinetics unaffected1 2 49 113

Used safely and effectively; combined therapy apparently somewhat more effective than esmolol alone in lowering heart rate59 113

Verapamil

Rare but serious adverse reactions (including fatal cardiac arrest) with concomitant IV β-blocker and IV verapamil, especially in patients with severe cardiomyopathy, heart failure, or recent MI1 141

Mibefradil (no longer commercially available in US)

Slowing or complete suppression of SA node activity, with slow ventricular rates139 140

Vasoconstrictors or inotropes (e.g., dopamine, epinephrine, norepinephrine)

Potential for blocked cardiac contractility when systemic vascular resistance is high1

Do not use esmolol to control SVT in patients receiving vasoconstrictive or inotropic drugs1

Catecholamine-depleting drugs (e.g., reserpine)

Possible additive effects1

Monitor closely for marked bradycardia or hypotension1

Morphine

Increased esmolol concentrations; morphine pharmacokinetics not affected1 2 49 113

Titrate esmolol dosage carefully1 2 49

Neuromuscular blocking agents (succinylcholine)

Possible prolonged duration of neuromuscular blockade1 2 113

Apparently not clinically important1 2 86 114

Warfarin

Slight increase in esmolol concentrations;1 2 49 113 warfarin concentrations not affected1 2 49 113

Titrate esmolol dosage carefully1
Esmolol drug interactions (more detail)

Esmolol Hydrochloride Pharmacokinetics

Absorption

Onset

Following rapid IV injection, 13–18% decrease in heart rate within 1 minute, 11–18% decrease in SBP within 2 minutes, and 13–22% prolongation of PR interval within 4 minutes after IV injection.41

In patients with SVT, 15–20% reduction in heart rate apparent within 5–22 minutes after initiation of IV infusion.59 68

Duration

Following discontinuance of IV infusion, β-blockade dissipates within about 1–2 minutes, substantial recovery occurs within about 10–20 minutes, and complete reversal occurs within about 20–30 minutes.1 2 5 27 34 39 113

Distribution

Extent

Distributed into liver and kidneys, but only minimally into CSF, spleen, or testes of rats.2 28 Rapidly and widely distributed in humans.2 39 99 113

Not known whether esmolol and/or ASL 8123 crosses the placenta in humans, 126 but the drug crosses the placenta in animals.114 115

Not known whether esmolol and/or ASL 8123 are distributed into milk.1

Plasma Protein Binding

Esmolol: 55%1 2 28 113 (albumin and α1-acid glycoprotein).28

Metabolite (ASL 8123): Approximately 10%.1 2 113

Elimination

Metabolism

Hydrolyzed rapidly, principally by esterases (probably arylesterase) in erythrocytic cytosol,1 2 39 40 45 46 99 113 to de-esterified (acid) metabolite (ASL 8123) and methanol.1 2 39 40 45 46 113 Acid metabolite has no appreciable β-blocking activity in humans.1 2 40

Elimination Route

Excreted principally in urine as the acid metabolite (73–88%); less than 2% excreted unchanged in urine.1 2 5 39 47 113 Small amounts (<5%) may be eliminated in feces.28 114

Half-life

Biphasic;1 2 39 99 113 distribution half-life of esmolol is about 2 minutes; 1 2 39 99 terminal elimination half-life is about 9 minutes (range: 5–23 minutes).1 2 39 40 99 114

Special Populations

In patients with renal impairment, elimination half-life of the metabolite may be increased up to 10-fold, but accumulation is not clinically important since ASL 8123 has only minimal β-blocking activity.2 43

About 24% (as metabolite) is removed by hemodialysis,114 and 21% by peritoneal dialysis;114 amount removed depends on several factors (e.g., dialysis flow-rate, dwell time).131 132 133 134

Stability

Storage

Parenteral

Injection

25°C (may be exposed to 15–30°C).1 a Do not freeze; protect from excessive heat.1 a

Actions

Advice to Patients

Additional Information

The American Society of Health-System Pharmacists, Inc. represents that the information provided in the accompanying monograph was formulated with a reasonable standard of care, and in conformity with professional standards in the field. Readers are advised that decisions regarding use of drugs are complex medical decisions requiring the independent, informed decision of an appropriate health care professional, and that the information contained in the monograph is provided for informational purposes only. The manufacturer’s labeling should be consulted for more detailed information. The American Society of Health-System Pharmacists, Inc. does not endorse or recommend the use of any drug. The information contained in the monograph is not a substitute for medical care.

Preparations

Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.

Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations.

* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name

Esmolol Hydrochloride

Routes

Dosage Forms

Strengths

Brand Names

Manufacturer

Parenteral

Injection, for IV use

10 mg/mL (100 mg)*

Brevibloc

Baxter

Esmolol Hydrochloride Injection
Esmolol Hydrochloride in Sodium Chloride

Routes

Dosage Forms

Strengths

Brand Names

Manufacturer

Parenteral

Injection, for IV use

10 mg/mL (2.5 g) in 0.59% Sodium Chloride Injection

Brevibloc Premixed

Baxter

20 mg/mL (2 g) in 0.41% Sodium Chloride Injection

Brevibloc Double Strength Premixed

Baxter

AHFS DI Essentials™. © Copyright 2025, Selected Revisions June 10, 2024. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814.

† Off-label: Use is not currently included in the labeling approved by the US Food and Drug Administration.

References

1. Baxter. Brevibloc injection (esmolol hydrochloride) prescribing information. (dated 1998 Jun). In: Physicians’ desk reference. 54th ed. Montvale NJ: Medical Economics Company Inc; 2000:655-7.

2. Du Pont Critical Care. Brevibloc (esmolol HCL) the ultrashort-acting intravenous beta blocker: technical monograph and formulary information. Waukegan, IL; 1987 Feb.

3. Angaran DM, Schultz NJ, Tschida VH. Esmolol hydrochloride: an ultrashort-acting, β-adrenergic blocking agent. Clin Pharm. 1986; 5:288-303. https://pubmed.ncbi.nlm.nih.gov/2871961

4. Covinsky JO. Esmolol: a novel cardioselective, titratable, intravenous beta-blocker with ultrashort half-life. Drug Intell Clin Pharm. 1987; 21:316-21. https://pubmed.ncbi.nlm.nih.gov/2882993

5. Benfield P, Sorkin EM. Esmolol: a preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs. 1987; 33:392-412. https://pubmed.ncbi.nlm.nih.gov/2885168

6. Erhardt PW, Woo CM, Gorczynski RJ et al. Ultra-short-acting β-adrenergic receptor blocking agents. Part 1: (aryloxy)propanolamines containing esters in the nitrogen substituent. J Med Chem. 1982; 25:1402-7. https://pubmed.ncbi.nlm.nih.gov/6130153

7. Erhardt PW, Woo CM, Anderson WG et al. Ultra-short-acting β-adrenergic receptor blocking agents. Part 2: (aryloxy)propanolamines containing esters on the aryl function. J Med Chem. 1982; 25:1408-12. https://pubmed.ncbi.nlm.nih.gov/6130154

8. Sum CY, Yacobi A. Gas chromatographic-mass spectrometric assay for the ultra-short-acting β-blocker esmolol. J Pharm Sci. 1984; 73:1177-9. https://pubmed.ncbi.nlm.nih.gov/6149299

9. Lee YC, Baaske DM, Alam AS. High-performance liquid chromatographic method for the determination of esmolol hydrochloride. J Pharm Sci. 1984; 73:1660-1. https://pubmed.ncbi.nlm.nih.gov/6520778

10. Mimnaugh MN, Gearien JE. Adrenergic drugs. In: Foye WO, ed. Principles of medicinal chemistry. 2nd ed. Philadelphia: Lea & Febiger; 1981:377-93.

11. Machin PJ, Hurst DN, Bradshaw RN et al. β1-Selective adrenoceptor antagonists. Part 2: 4-ether-linked phenoxypropanolamines. J Med Chem. 1983; 26:1570-6. https://pubmed.ncbi.nlm.nih.gov/6138435

12. Woods PB, Robinson ML. An investigation of the comparative liposolubilities of β-adrenoceptor blocking agents. J Pharm Pharmacol. 1981; 33:172-3. https://pubmed.ncbi.nlm.nih.gov/6116760

13. Zaroslinski J, Borgman RJ, O’Donnell JP et al. Ultra-short acting beta-blockers: a proposal for the treatment of the critically ill patient. Life Sci. 1982; 31:899-907. https://pubmed.ncbi.nlm.nih.gov/6129559

14. Schultz NJ, Angaran DM. Esmolol hydrochloride: an ultra-short acting / blocker. Clin Pharm. 1984; 3:447,50.

15. Keefe DL, Somberg JC. Esmolol: a novel ultra-short-acting beta-blocking agent. J Clin Pharmacol. 1986; 26(Suppl A):A1-2.

16. Sonnenblick EH. A symposium: esmolol—an ultra-short-acting intravenous beta blocker. Introduction. Am J Cardiol. 1985; 56(Suppl):1-2F. https://pubmed.ncbi.nlm.nih.gov/4014012

17. Gorczynski RJ, Shaffer JE, Lee RJ. Pharmacology of ASL-8052, a novel β-adrenergic receptor antagonist with an ultrashort duration of action. J Cardiovasc Pharmacol. 1983; 5:668-77. https://pubmed.ncbi.nlm.nih.gov/6193366

18. Gorczynski RJ, Murthy VS, Hwang TF. β-blocking and hemodynamic effects of ASL-8052. J Cardiovasc Pharmacol. 1984; 6:1048-59.

19. Murthy VS, Hwang TF, Zagar ME et al. Cardiovascular pharmacology of ASL-8052, an ultra-short acting β blocker. Eur J Pharmacol. 1983; 94:43-51. https://pubmed.ncbi.nlm.nih.gov/6140172

20. Lange R, Kloner RA, Braunwald E. First ultra-short-acting beta-adrenergic blocking agent: its effect on size and segmental wall dynamics of reperfused myocardial infarcts in dogs. Am J Cardiol. 1983; 51:1759-67. https://pubmed.ncbi.nlm.nih.gov/6134464

21. Kloner RA. Kirshenbaum J, Lange R et al. Experimental and clinical observations on the efficacy of esmolol in myocardial ischemia. Am J Cardiol. 1985; 56(Suppl):40-8F.

22. Iskandrian AS, Hakki AH, Laddu A. Effects of esmolol on cardiac function: evaluation by noninvasive techniques. Am J Cardiol. 1985; 56(Suppl):27-32F. https://pubmed.ncbi.nlm.nih.gov/4014036

23. Iskandrian AS, Hakki AH, Laddu A et al. Effects of intravenous infusion of esmolol and propranolol on biventricular performance at rest and during exercise as assessed by quantitative radionuclide angiography. Am J Cardiol. 1985; 55:1287-92. https://pubmed.ncbi.nlm.nih.gov/3993558

24. Kirshenbaum JM, Kloner RA, Antman EM et al. Use of an ultra short-acting β-blocker in patients with acute myocardial ischemia. Circulation. 1985; 72:873-80. https://pubmed.ncbi.nlm.nih.gov/2863013

25. Iskandrian AS, Bemis CE, Hakki AH et al. Effects of esmolol on patients with left ventricular dysfunction. J Am Coll Cardiol. 1986; 8:225-31. https://pubmed.ncbi.nlm.nih.gov/2872244

26. Dickerson D, Paulos M, Klein J et al. Beta blocking action of esmolol, an ultra short acting beta blocking agent. Clin Res. 1983; 31:179A.

27. Reilly CS, Wood M, Koshakji RP et al. Ultra-short-acting beta-blockade: a comparison with conventional beta-blockade. Clin Pharmacol Ther. 1985; 38:579-85. https://pubmed.ncbi.nlm.nih.gov/2865029

28. Reynolds RD, Gorczynski RJ, Quon CY. Pharmacology and pharmacokinetics of esmolol. J Clin Pharmacol. 1986; 26(Suppl A):A3-14. https://pubmed.ncbi.nlm.nih.gov/2870084

29. Gorczynski RJ. Basic pharmacology of esmolol. Am J Cardiol. 1985; 56(Suppl):3-13F.

30. Prichard BNC. β-Adrenergic receptor blockade in hypertension, past, present and future. Br J Clin Pharmacol. 1978; 5:379-99. https://pubmed.ncbi.nlm.nih.gov/26370

31. Thadani U. Beta blockers in hypertension. Am J Cardiol. 1983; 52(Suppl):10-5D.

32. Weiner N. Drugs that inhibit adrenergic nerves and block adrenergic receptors. In: Gilman AG, Goodman LS, Rall TW et al, eds. Goodman and Gilman’s the pharmacological basis of therapeutics. 7th ed. New York: Macmillan Publishing Company; 1985:181-214.

33. Bigger JT Jr, Hoffman BF. Antiarrhythmic drugs. In: Gilman AG, Goodman LS, Rall TW et al, eds. Goodman and Gilman’s the pharmacological basis of therapeutics. 7th ed. New York: Macmillan Publishing Company; 1985:748-83.

34. Greenspan AM, Spielman SR, Horowitz LN et al. Electrophysiology of esmolol. Am J Cardiol. 1985; 56(Suppl):19-24F.

35. Sheppard D, DiStefano S, Byrd RC et al. Effects of esmolol on airway function in patients with asthma. J Clin Pharmacol. 1986; 26:169-74. https://pubmed.ncbi.nlm.nih.gov/2870080

36. Askenazi J, Hoff JV, Turlapaty P et al. The effect of esmolol on cardiac hemodynamic function. Clin Res. 1985; 33:167A.

37. Menkhaus PG, Reves JG, Kissin I et al. Cardiovascular effects of esmolol in anesthetized humans. Anesth Analg. 1985; 64:327-34. https://pubmed.ncbi.nlm.nih.gov/2858169

38. de Bruijn NP, Croughwell N, Reves JG. Hemodynamic effects of esmolol in chronically β-blocked patients undergoing aortocoronary bypass surgery. Anesth Analg. 1987; 66:137-41. https://pubmed.ncbi.nlm.nih.gov/2880530

39. Sum CY, Yacobi A, Kartzinel R et al. Kinetics of esmolol, an ultra-short-acting beta blocker, and of its major metabolite. Clin Pharmacol Ther. 1983; 34:427-34. https://pubmed.ncbi.nlm.nih.gov/6617063

40. Yacobi A, Kartzinel R, Lai CM et al. Esmolol: a pharmacokinetic profile of a new cardioselective β-blocking agent. J Pharm Sci. 1983; 72:710-1. https://pubmed.ncbi.nlm.nih.gov/6135794

41. Ellenbogen KA, McCarthy EA, Pritchett ELC. Effects of bolus injection of esmolol in healthy, exercising subjects. Clin Pharmacol Ther. 1987; 41:455-9. https://pubmed.ncbi.nlm.nih.gov/3829581

42. Sintetos AL, Hulse J, Pritchett ELC. Pharmacokinetics and pharmacodynamics of esmolol administered as an intravenous bolus. Clin Pharmacol Ther. 1987; 41:112-7. https://pubmed.ncbi.nlm.nih.gov/2879662

43. Flaherty J, Wong B, LaFollette G et al. Kinetics of esmolol and ASL-8123 in normals and in renal failure. Clin Pharmacol Ther. 1986; 39:192.

44. Rollins D, Buchi K, Tolman K et al. Pharmacokinetics of esmolol in hepatic disease. Clin Pharmacol Ther. 1986; 39:224.

45. Quon CY, Stampfli HF. Biochemical properties of blood esmolol esterase. Drug Metab Dispos. 1985; 13:420-4. https://pubmed.ncbi.nlm.nih.gov/2863104

46. Stampfli HF, Lai CM, Yacobi A et al. High-performance liquid chromatographic assay for the major blood metabolite of esmolol—an ultra short acting beta blocker. J Chromatogr. 1984; 309:203-8. https://pubmed.ncbi.nlm.nih.gov/6148350

47. Achari R, Drissel D, Matier WL et al. Metabolism and urinary excretion of esmolol in humans. J Clin Pharmacol. 1986; 26:44-7. https://pubmed.ncbi.nlm.nih.gov/2869058

48. Paulos M, Laddu A, Kartzinel R et al. Beta blocking activity of esmolol, a new ultra short acting beta blocking agent. Clin Res. 1983; 31:212A.

49. Lowenthal DT, Porter RS, Saris SD et al. Clinical pharmacology, pharmacodynamics and interactions with esmolol. Am J Cardiol. 1985; 56(Suppl):14-8F.

50. Klein G, Wirtzfeld A, Alt E et al. Antiarrhythmic activity of esmolol (ASL-8052)—a novel ultra-short acting beta-adrenoreceptor blocking agent. Int J Clin Pharmacol Ther Toxicol. 1984; 22:112-7. https://pubmed.ncbi.nlm.nih.gov/6142005

51. Anderson S, Blanski L, Byrd RC et al. Comparison of the efficacy and safety of esmolol, a short-acting beta blocker, with placebo in the treatment of supraventricular tachyarrhythmias. Am Heart J. 1986; 111:42-8. https://pubmed.ncbi.nlm.nih.gov/2868645

52. Byrd RC, Sung RJ, Marks J et al. Safety and efficacy of esmolol (ASL-8052: an ultrashort-acting beta-adrenergic blocking agent) for control of ventricular rate in supraventricular tachycardias. J Am Coll Cardiol. 1984; 3:394-9. https://pubmed.ncbi.nlm.nih.gov/6141193

53. Morganroth J, Horowitz LN, Anderson J et al. Comparative efficacy and tolerance of esmolol to propranolol for control of supraventricular tachyarrhythmia. Am J Cardiol. 1985; 56(Suppl):33-9F.

54. Abrams J, Allen J, Allin D et al. Efficacy and safety of esmolol vs propranolol in the treatment of supraventricular tachyarrhythmias: a multicenter double-blind clinical trial. Am Heart J. 1985; 110:913-22. https://pubmed.ncbi.nlm.nih.gov/3904379

55. Allin D, Anderson S, Angaran D et al. Intravenous esmolol for the treatment of supraventricular tachyarrhythmia: results of a multicenter, baseline-controlled safety and efficacy study in 160 patients. Am Heart J. 1986; 112:498-505. https://pubmed.ncbi.nlm.nih.gov/2875641

56. Schultz NJ, Tschida VH, Arom KV et al. Antidysrhythmic efficacy and safety of esmolol: an ultra-short-acting cardioselective β-blocker. Drug Intell Clin Pharm. 1984; 18:496.

57. Das G, Barr C, Ferris J. Management of supraventricular tachycardia with esmolol hydrochloride. Clin Pharmacol Ther. 1985; 37:189.

58. Sung RJ, Blanski L, Kirshenbaum J et al. Clinical experience with esmolol, a short-acting beta-adrenergic blocker in cardiac arrhythmias and myocardial ischemia. J Clin Pharmacol. 1986; 26(Suppl A):A15-26. https://pubmed.ncbi.nlm.nih.gov/2870082

59. Gray RJ, Bateman TM, Czer LSC et al. Esmolol: a new ultrashort-acting beta-adrenergic blocking agent for rapid control of heart rate in postoperative supraventricular tachyarrhythmias. J Am Coll Cardiol. 1985; 5:1451-6. https://pubmed.ncbi.nlm.nih.gov/2860148

60. Reves JG, Flezzani P. Perioperative use of esmolol. Am J Cardiol. 1985; 56(Suppl):57-62F.

61. Girard D, Shulman BJ, Thys DM et al. The safety and efficacy of esmolol during myocardial revascularization. Anesthesiology. 1986; 65:157-64. https://pubmed.ncbi.nlm.nih.gov/3526984

62. Korenaga GM, Kirkpatrick A, Lord JG. Effect of esmolol on tachycardia induced by endotracheal intubation. Anesth Analg. 1985; 64:238.

63. Cucchiara RF, Benefiel DJ, Matteo RS et al. Evaluation of esmolol in controlling increases in heart rate and blood pressure during endotracheal intubation in patients undergoing carotid endarterectomy. Anesthesiology. 1986; 65:528-31. https://pubmed.ncbi.nlm.nih.gov/2877599

64. Ebert J, Gelman S, Coverman S et al. Effect of esmolol on the heart rate and blood pressure response during endotracheal intubation. Anesthesiology. 1985; 63:A63.

65. Kaplan JA, Thys DM, Girard D et al. Hemodynamic effects of esmolol during myocardial revascularization. In: Kaplan JA, ed. Esmolol and the adrenergic response to perioperative stimuli: proceedings from a symposium; 1985 Oct 13; San Francisco, CA. New York: Biomedical Information Corp; 1986:53-60.

66. Newsome LR, Roth JV, Hug CC Jr et al. Esmolol attenuates hemodynamic responses during fentanyl-pancuronium anesthesia for aortocoronary bypass surgery. Anesth Analg. 1986; 65:451-6. https://pubmed.ncbi.nlm.nih.gov/3485937

67. Henling CE, Reves JG, Samuelson PN et al. Hemodynamic effects of continuous infusion of esmolol during cardiac operation. Anesth Analg. 1986; 65:S70. https://pubmed.ncbi.nlm.nih.gov/2937351

68. Schwartz M, Michelson EL, Sawin HS et al. Efficacy and safety of esmolol for postoperative atrial fibrillation/flutter. Clin Res. 1985; 33:A748.

69. Murthy VS, Patel KD, Elangovan RG et al. Cardiovascular and neuromuscular effects of esmolol during induction of anesthesia. J Clin Pharmacol. 1986; 26:351-7. https://pubmed.ncbi.nlm.nih.gov/2871054

70. Liu PL, Gatt S, Gugino LD et al. Esmolol for control of increases in heart rate and blood pressure during tracheal intubation after thiopentone and succinylcholine. Can Anaesth Soc J. 1986; 33:556-62. https://pubmed.ncbi.nlm.nih.gov/3768764

71. Gold MI, Brindle F, Liu P et al. The effect of esmolol on heart rate and blood pressure during induction and tracheal intubation: a double-blind, randomized, multicenter study. In: Kaplan JA, ed. Esmolol and the adrenergic response to perioperative stimuli: proceedings from a symposium; 1985 Oct 13; San Francisco, CA. New York: Biomedical Information Corp; 1986:53-60.

72. Anderson W, Brindle F, Liu P et al. Effect of esmolol on heart rate and blood pressure during intubation in relatively healthy patients. Anesthesiology. 1985; 63:A104.

73. Gold MI, Brown M, Coverman S et al. Heart rate and blood pressure effects of esmolol after ketamine induction and intubation. Anesthesiology. 1986; 64:718-23. https://pubmed.ncbi.nlm.nih.gov/3717635

74. Gray RJ, Bateman TM, Czer LSC et al. Use of esmolol in hypertension after cardiac surgery. Am J Cardiol. 1985; 56(Suppl):49-56F.

75. Ornstein E, Matteo RS, Schwartz AE et al. The use of esmolol for deliberate hypotension. Anesthesiology. 1986; 65:A575. https://pubmed.ncbi.nlm.nih.gov/3752581

76. Replogle R, Levy M, DeWall RA et al. Catecholamine and serotonin response to cardiopulmonary bypass. J Thorac Cardiovasc Surg. 1962; 44:638-48. https://pubmed.ncbi.nlm.nih.gov/13981705

77. Lillehei RC, Lillehei CW, Grismer JT et al. Plasma catecholamines in open-heart surgery; prevention of their pernicious effects by pretreatment with dibenzyline. Surg Forum. 1963; 14:269-71. https://pubmed.ncbi.nlm.nih.gov/14064552

78. Braunwald E, Muller JE, Kloner RA et al. Role of beta-adrenergic blockade in the therapy of patients with myocardial infarction. Am J Med. 1983; 74:113-23. https://pubmed.ncbi.nlm.nih.gov/6129798

79. Frishman WH, Furberg CD, Friedewald WT. β-Adrenergic blockade for survivors of acute myocardial infarction. New Engl J Med. 1984; 310:830-6. https://pubmed.ncbi.nlm.nih.gov/6142420

80. Frishman WH, Furberg CD, Friedewald WT. The use of β-adrenergic blocking drugs in patients with myocardial infarction. Curr Probl Cardiol J. 1984; 9:1-50.

81. Slogoff S, Keats AS. Does perioperative myocardial ischemia lead to postoperative myocardial infarction? Anesthesiology. 1985; 62:107-14.

82. Wallis DE, Pope CM, Littman WJ et al. Esmolol versus propranolol in the management of unstable angina. Clin Res. 1986; 34:904A.

83. Kim YD, Jones M, Hanowell ST et al. Changes in peripheral vascular and cardiac sympathetic activity before and after coronary artery bypass surgery: interrelationships with hemodynamic alterations. Am Heart J. 1981; 102:972-9. https://pubmed.ncbi.nlm.nih.gov/6976114

84. McCammon RL, Hilgenberg JC, Sandage BW Jr et al. The effect of esmolol on the onset and duration of succinylcholine-induced neuromuscular blockade. Anesthesiology. 1985; 63:A317.

85. Barabas E, Zsigmond EK, Kirkpatrick AF. The inhibitory effect of esmolol on human plasmacholinesterase. Can Anaesth Soc J. 1986; 33:332-5. https://pubmed.ncbi.nlm.nih.gov/3719434

86. Murthy VS, Patel KD, Elangovan RG et al. Effects of esmolol on circulatory response to intubation and succinylcholine-induced neuromuscular blockade in man. Anesthesiology. 1985; 63:A361.

87. Angaran D, Fitzpatrick P, Gray R et al. Antiarrhythmic efficacy and safety of esmolol—an ultra-short acting beta-blocker. Clin Res. 1984; 32:148A.

88. Michelson EL, Porterfield JK, Das G et al. A comparison of esmolol and verapamil in the treatment of atrial fibrillation/flutter. J Am Coll Cardiol. 1986; 7:157A.

89. Harris FJ, Low RI, Paumer L et al. Antianginal efficacy and improved exercise performance with timolol: twice-daily beta blockade in ischemic heart disease. Am J Cardiol. 1983; 51:13-8. https://pubmed.ncbi.nlm.nih.gov/6129794

90. Miller RR, Olson HG, Pratt CM et al. Efficacy of beta adrenergic blockade in coronary heart disease: propranolol in angina pectoris. Clin Pharmacol Ther. 1975; 18:598-605. https://pubmed.ncbi.nlm.nih.gov/810295

91. Aronow WS, Van Camp S, Turbow M et al. Acebutolol in supraventricular arrhythmias. Clin Pharmacol Ther. 1979; 25:149-53. https://pubmed.ncbi.nlm.nih.gov/365429

92. Thadani U. Beta blockers in hypertension. Am J Cardiol. 1983; 52(Suppl):10-5D.

93. Goldman L. Cardiac risks and complications of noncardiac surgery. Ann Intern Med. 1983; 98:504-13. https://pubmed.ncbi.nlm.nih.gov/6340579

94. Smulyan H, Weinberg SE, Howanitz PJ. Continuous propranolol infusion following abdominal surgery. JAMA. 1982; 247:2539-42. https://pubmed.ncbi.nlm.nih.gov/7069919

95. Reves JG, Knopes KD. Adrenergic component of the stress response: implications in the perioperative period. In: Kaplan JA, ed. Esmolol and the adrenergic response to perioperative stimuli: proceedings from a symposium; 1985 Oct 13; San Francisco, CA. New York: Biomedical Information Corp; 1986:53-60.

96. Goldman L. Noncardiac surgery in patients receiving propranolol: case reports and a recommended approach. Arch Intern Med. 1981; 141:193-6. https://pubmed.ncbi.nlm.nih.gov/7458515

97. Villers D, Pinaud MLJ, Bourin M et al. Propranolol postoperative maintenance by continuous intravenous infusion. Anesthesiology. 1984; 60:594-8. https://pubmed.ncbi.nlm.nih.gov/6731917

98. Stella VJ. Chemical and physical bases determining the instability and incompatibility of formulated injectable drugs. J Parenter Sci Technol. 1986; 40:142-63. https://pubmed.ncbi.nlm.nih.gov/3534205

99. de Bruijn NP, Reves JG, Croughwell N et al. Pharmacokinetics of esmolol in anesthetized patients receiving chronic beta blocker therapy. Anesthesiology. 1987; 66:323-6. https://pubmed.ncbi.nlm.nih.gov/2881504

100. Anon. Esmolol—a short-acting IV beta-blocker. Med Lett Drugs Ther. 1987; 29:57-8. https://pubmed.ncbi.nlm.nih.gov/2884558

101. Harrison L, Ralley FE, Wynands E et al. The role of an ultra short-acting adrenergic blocker (esmolol) in patients undergoing coronary artery bypass surgery. Anesthesiology. 1987; 66:413-6. https://pubmed.ncbi.nlm.nih.gov/2881505

102. Lange R, Kloner RA, Braunwald E. Enhancement of functional recovery of “stunned”, reperfused myocardium by a new ultra-short-acting beta-blocker. J Am Coll Cardiol. 1984; 3:545.

103. Martin DE, Kammerer WS. The hypertensive surgical patient: controversies in management. Surg Clin North Am. 1983; 63:1017-33. https://pubmed.ncbi.nlm.nih.gov/6138862

104. Wyeth Laboratories Inc. Sectral (acebutolol hydrochloride) capsules prescribing information. Philadelphia, PA; 1986 Feb.

105. Greefhorst APM, van Herwaarden CLA. Comparative study of the ventilatory effects of three beta1-selective blocking agents in asthmatic patients. Eur J Clin Pharmacol. 1981; 20:417-21. https://pubmed.ncbi.nlm.nih.gov/6116610

106. Decalmer PBS, Chatterjee SS, Cruickshank JM et al. Beta-blockers and asthma. Br Heart J. 1978; 40:184-9. https://pubmed.ncbi.nlm.nih.gov/25075

107. Tattersfield AE, Harrison RN. Effect of β-blocker therapy on airway function. Drugs. 1983; 25(Suppl 2):227-31.

108. Jackson JE, Bressler R. Clinical pharmacology of sulphonylurea hypoglycaemic agents: part 2. Drugs. 1981; 22:295-320. https://pubmed.ncbi.nlm.nih.gov/7030708

109. Gray RJ, Bateman TM, Czer LSC et al. Comparison of esmolol and nitroprusside for acute post-cardiac surgical hypertension. Am J Cardiol. 1987; 59:887-91. https://pubmed.ncbi.nlm.nih.gov/2881481

110. Frishman W, Jacob H, Eisenberg E et al. Clinical pharmacology of the new β-adrenergic blocking drugs. Part 8: self-poisoning with beta-adrenoceptor blocking agents: recognition and management. Am Heart J. 1979; 98:798-811. https://pubmed.ncbi.nlm.nih.gov/40429

111. Weinstein RS. Recognition and management of poisoning with beta-adrenergic blocking agents. Ann Emerg Med. 1984; 13:1123-31. https://pubmed.ncbi.nlm.nih.gov/6150667

112. Anon. Beta-blocker poisoning. Lancet. 1980; 1:803-4.

113. Turlapaty P, Laddu A, Murthy VS et al. Esmolol: a titratable short-acting intravenous beta blocker for acute critical care settings. Am Heart J. 1987; 114:866-85. https://pubmed.ncbi.nlm.nih.gov/2889341

114. Toole JG (Dupont Critical Care, Waukegan, IL): Personal communication; 1987 Dec 3.

115. Ostman LGP, Chestnut DM, Robillard JE et al. Assessment of transplacental passage and hemodynamic effects of esmolol in the gravid ewe. Anesthesiology. 1987; 67:A635.

116. Gribbin HR, Baldwin CJ, Tattersfield AE. Quantitative assessment of bronchial β-adrenoceptor blockade in man. Br J Clin Pharmacol. 1979; 7:551-6. https://pubmed.ncbi.nlm.nih.gov/37867

117. Tattersfield AE, Holgate ST, Harvey JE et al. Is asthma due to partial beta-blockade of airways? Thorax. 1982; 37:779-80. Abstract.

118. Baky SH, Singh BN. Verapamil hydrochloride: pharmacological properties and role in cardiovascular therapeutics. Pharmacotherapy. 1982; 2:328-53. https://pubmed.ncbi.nlm.nih.gov/6762530

119. Thomson DF, Thomson GD. Compatibility of furosemide with esmolol infusions. Am J Hosp Pharm. (in press)

120. Rehnquist N. Clinical experience with intravenous metoprolol in supraventricular tachyarrhythmias. A multicenter study. Ann Clin Res. 1981; 13(Suppl 30):68. https://pubmed.ncbi.nlm.nih.gov/7027895

121. Williams DO, Tatelbaum R, Most AS. Effective treatment of supraventricular arrhythmias with acebutolol. Am J Cardiol. 1979; 44:521. https://pubmed.ncbi.nlm.nih.gov/382821

122. Morganroth J, MacCosbe P, Bell V et al. Management of postoperative supraventricular tachycardia: comparative efficacy and safety of esmolol v propranolol in 65 patients. In: Kaplan JA, ed. Esmolol and the adrenergic response to perioperative stimuli: proceedings from a symposium; 1985 Oct 13; San Francisco, CA. New York: Biomedical Information Corp; 1986:53-60.

123. Bunegin L, Albin MS, Gelineau EF. Effect of esmolol on cerebral blood flow during intracranial hypertension and hemorrhagic hypovolemia. Anesthesiology. 1987; 67:A424.

124. Ornstein E, Matteo RS, Weinstein JA et al. A randomized controlled trial of esmolol for deliberate hypotension. Anesthesiology. 1987; 67:A423.

125. Reves JG, Croughwell N, Hawkins E et al. Esmolol for treatment of intraoperative tachycardia and/or hypertension—bolus loading technique. Anesthesiology. 1987; 67:A33.

126. Reviewers’ comments (personal observations); 1987 Nov.

127. Frishman W, Jacob H, Eisenberg E et al. Clinical pharmacology of the new β-adrenergic blocking drugs. Part 8. Self-poisoning with beta-adrenoceptor blocking agents: recognition and management. Am Heart J. 1979; 98:798-811. https://pubmed.ncbi.nlm.nih.gov/40429

128. Weinstein RS. Recognition and management of poisoning with beta-adrenergic blocking agents. Ann Emerg Med. 1984; 13:1123-31. https://pubmed.ncbi.nlm.nih.gov/6150667

129. Anon. Beta-blocker poisoning. Lancet. 1980; 1:803-4.

130. Du Pont Critical Care. Esmolol toxicology summary. Waukegan, IL; 1987 Aug.

131. Gibson TP, Matusik E, Nelson LD et al. Artificial kidneys and clearance calculations. Clin Pharmacol Ther. 1976; 20:720-6. https://pubmed.ncbi.nlm.nih.gov/991541

132. Pond S, Rosenberg J, Benowitz NL et al. Pharmacokinetics of haemoperfusion for drug overdose. Clin Pharmacokinet. 1979; 4:329-54. https://pubmed.ncbi.nlm.nih.gov/389527

133. Lee CSC, Marbury TC. Drug therapy in patients undergoing haemodialysis: clinical pharmacokinetic considerations. Clin Pharmacokinet. 1984; 9:42-66. https://pubmed.ncbi.nlm.nih.gov/6362952

134. Pond SM. Renal principles: diuresis, dialysis, and hemoperfusion. In: Goldfrank’s toxicologic emergencies. 3rd ed. Norwalk, CT: Appleton-Century-Crofts; 1986:102-15.

136. Pearce DJ. Brevibloc drug errors. Can J Anaesth. 1996; 43:419. https://pubmed.ncbi.nlm.nih.gov/8697563

137. Cohen MR. Esmolol (Brevibloc) ampules can pose danger in critical care. Hosp Pharm. 1996: 31:88.

138. Raza A. Brevibloc drug errors. Can J Anaesth. 1996; 43:419.

139. Roche. Posicor (mibefradil hydrochloride) tablets prescribing information. Nutley, NJ; 1997 Dec.

140. Ellison RH. Dear doctor letter regarding appropriate use of Posicor. Nutley, NJ: Roche Laboratories; 1997 Dec.

141. Knoll Laboratories. Isoptin (verapamil hydrochloride) intravenous injection prescribing information. In: Physicians’ desk reference. 52nd ed. Montvale, NJ: Medical Economics Company Inc; 1998:1354-6.

145. Braunwald E, Jones RH, Mark DB et al. Diagnosing and managing unstable angina. Quick reference guide for clinicians. Circulation. 1994; 90:613-22. https://pubmed.ncbi.nlm.nih.gov/8026048

155. Conolly ME, Kersting F, Dollery CT. The clinical pharmacology of beta-adrenoceptor-blocking drugs. Prog Cardiovasc Dis. 1976; 19:203-34. https://pubmed.ncbi.nlm.nih.gov/10600

156. Shand DG. State-of-the-art: comparative pharmacology of the β-adrenoceptor blocking drugs. Drugs. 1983; 25(Suppl 2):92-9.

157. Breckenridge A. Which beta blocker? Br Med J. 1983; 286:1085-8. (IDIS 169422)

158. Anon. Choice of a beta-blocker. Med Lett Drugs Ther. 1986; 28:20-2. https://pubmed.ncbi.nlm.nih.gov/2869400

159. Wallin JD, Shah SV. β-Adrenergic blocking agents in the treatment of hypertension: choices based on pharmacological properties and patient characteristics. Arch Intern Med. 1987; 147:654-9. https://pubmed.ncbi.nlm.nih.gov/2881524

160. McDevitt DG. β-Adrenoceptor blocking drugs and partial agonist activity: is it clinically relevant? Drugs. 1983; 25:331-8.

161. McDevitt DG. Clinical significance of cardioselectivity: state-of-the-art. Drugs. 1983; 25(Suppl 2):219-26.

162. Frishman WH. β-Adrenoceptor antagonists: new drugs and new indications. N Engl J Med. 1981; 305:500-6. https://pubmed.ncbi.nlm.nih.gov/6114433

163. Thadani U, Davidson C, Chir B et al. Comparison of the immediate effects of five β-adrenoceptor-blocking drugs with different ancillary properties in angina pectoris. N Engl J Med. 1979; 300:750-5. https://pubmed.ncbi.nlm.nih.gov/581782

164. Lewis RV, McDevitt DG. Adverse reactions and interactions with β-adrenoceptor blocking drugs. Med Toxicol. 1986; 1:343-61. https://pubmed.ncbi.nlm.nih.gov/2878346

165. Frishman WH. Clinical differences between beta-adrenergic blocking agents: implications for therapeutic substitution. Am Heart J. 1987; 113:1190-8. https://pubmed.ncbi.nlm.nih.gov/2883867

166. Douglas JG, Bakris GL, Epstein M et al. Management of high blood pressure in African Americans: Consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks. Arch Intern Med. 2003; 163:525-41.

249. ASHP. Standardize 4 Safety: pediatric continuous infusion standard. Updated 2024 Mar. From ASHP website. Updates may be available at ASHP website. https://www.ashp.org/standardize4safety

250. ASHP. Standardize 4 Safety: adult continuous infusion standard. Updated 2024 Mar. From ASHP website. Updates may be available at ASHP website. https://www.ashp.org/standardize4safety

300. Page RL, Joglar JA, Caldwell MA et al. 2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2016; 67:e27-e115.

301. January CT, Wann LS, Alpert JS et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014; 64:e1-76. https://pubmed.ncbi.nlm.nih.gov/24685669

502. Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013; 31:1281-357. https://pubmed.ncbi.nlm.nih.gov/23817082

527. O'Gara PT, Kushner FG, Ascheim DD et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013; 127:e362-425.

542. Marik PE, Varon J. Hypertensive crises: challenges and management. Chest. 2007; 131:1949-62. https://pubmed.ncbi.nlm.nih.gov/17565029

600. Baxter. Brevibloc (esmolol hydrochloride) injection prescribing information. Deerfield, IL; 2011 Feb.

801. Chen ZM, Pan HC, Chen YP et al. Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet. 2005; 366:1622-32. https://pubmed.ncbi.nlm.nih.gov/16271643

1100. Amsterdam EA, Wenger NK, Brindis RG et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014; 130:e344-426.

1150. Flynn JT, Kaelber DC, Baker-Smith CM et al. Clinical practice guideline for screening and management of high blood pressure in children and adolescents. Pediatrics. 2017; 140 https://pubmed.ncbi.nlm.nih.gov/28827377

1200. Whelton PK, Carey RM, Aronow WS et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018; 71:el13-e115. https://pubmed.ncbi.nlm.nih.gov/29133356

1235. Mann SJ. Redefining beta-blocker use in hypertension: selecting the right beta-blocker and the right patient. J Am Soc Hypertens. 2017; 11(1):54-65. https://pubmed.ncbi.nlm.nih.gov/28057444

a. Brevibloc (esmolol hydrochloride) injection prescribing information. In: PDR.net [database online]. Montvale, NJ: Thomson Healthcare; 2004. Updated (2003 Jun)

HID. Trissel LA. Handbook on injectable drugs. 17th ed. Bethesda, MD: American Society of Health-System Pharmacists; 2013:457-61.

Medical Disclaimer